[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,825
  • Shares Outstanding, K 27,453
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,430 K
  • EBIT $ -56 M
  • EBITDA $ -56 M
  • 60-Month Beta 1.03
  • Price/Sales 1.75
  • Price/Cash Flow N/A
  • Price/Book 0.18
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.13
  • Most Recent Earnings $-0.95 on 05/15/26
  • Next Earnings Date 08/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 589.49% (-265.73%)
  • Historical Volatility 111.59%
  • IV Percentile 93%
  • IV Rank 56.68%
  • IV High 994.89% on 06/05/26
  • IV Low 58.96% on 01/20/26
  • Expected Move (DTE 5) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 1,482
  • Open Int (30-Day) 1,999
  • Expected Range 0.5400 to 0.5400

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 1
  • High Estimate $-0.36
  • Low Estimate $-0.36
  • Prior Year $-0.80
  • Growth Rate Est. (year over year) +55.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4760 +13.45%
on 05/18/26
0.7546 -28.44%
on 05/14/26
-0.0730 (-11.91%)
since 05/12/26
3-Month
0.4760 +13.45%
on 05/18/26
1.0300 -47.57%
on 04/23/26
-0.3275 (-37.75%)
since 03/12/26
52-Week
0.4760 +13.45%
on 05/18/26
2.4800 -78.23%
on 07/03/25
-0.3800 (-41.30%)
since 06/12/25

Most Recent Stories

More News
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated...

CTXR : 0.5400 (-5.69%)
CTOR : 0.6640 (-4.12%)
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy

CTXR : 0.5400 (-5.69%)
CTOR : 0.6640 (-4.12%)
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ®

CTXR : 0.5400 (-5.69%)
CTOR : 0.6640 (-4.12%)
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $36.5 million in debt and equity capital secured Broad...

CTXR : 0.5400 (-5.69%)
CTOR : 0.6640 (-4.12%)
Citius Oncology Ships First International Order of LYMPHIRâ„¢ to Europe

Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch

CTXR : 0.5400 (-5.69%)
CTOR : 0.6640 (-4.12%)
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

CRANFORD, N.J. , April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 0.5400 (-5.69%)
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

CRANFORD, N.J. , April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 0.5400 (-5.69%)
Citius Oncology Provides Commercial Update on LYMPHIRâ„¢ Launch Highlighting Early Adoption and Expanding Clinical Development

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration

CTXR : 0.5400 (-5.69%)
CTOR : 0.6640 (-4.12%)
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIRâ„¢ in Discussions with Leading Cutaneous Lymphoma Experts

Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings available

CTXR : 0.5400 (-5.69%)
CTOR : 0.6640 (-4.12%)
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy

CTXR : 0.5400 (-5.69%)
CTOR : 0.6640 (-4.12%)

Business Summary

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 0.6398
2nd Resistance Point 0.6199
1st Resistance Point 0.5799
Last Price 0.5400
1st Support Level 0.5200
2nd Support Level 0.5001
3rd Support Level 0.4601

See More

52-Week High 2.4800
Fibonacci 61.8% 1.7145
Fibonacci 50% 1.4780
Fibonacci 38.2% 1.2415
Last Price 0.5400
52-Week Low 0.4760

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.